X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accesswire.com/869940/protagonist-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-2024
https://www.accesswire.com/863148/protagonist-therapeutics-announces-oral-presentation-on-long-term-follow-up-of-rusfertide-phase-2-revive-study-open-label-extension-at-the-european-hematology-association-2024-congress
https://feeds.issuerdirect.com/news-release.html?newsid=5003875791942536
https://www.accesswire.com/860498/protagonist-therapeutics-to-participate-in-the-citizens-jmp-life-sciences-conference-and-the-capital-one-1st-annual-biotechbiopharma-disruptors-event
https://www.accesswire.com/860223/protagonist-reports-first-quarter-2024-financial-results-and-provides-corporate-update
https://www.accesswire.com/846779/protagonist-therapeutics-provides-update-on-verify-patient-enrollment-and-timing-of-top-line-data
https://www.accesswire.com/843636/protagonist-therapeutics-announces-closing-of-worldwide-rusfertide-license-and-collaboration-agreement-with-takeda
https://www.accesswire.com/841100/late-breaking-presentation-at-american-academy-of-dermatology-2024-annual-meeting-shows-that-jnj-2113-the-first-and-only-investigational-targeted-oral-peptide-maintained-skin-clearance-in-moderate-to-severe-plaque-psoriasis-through-one-year
https://www.accesswire.com/840017/protagonist-therapeutics-to-participate-in-upcoming-investor-conferences
Market Place
Share 
